AtriCure Company Profile (NASDAQ:ATRC)

About AtriCure (NASDAQ:ATRC)

AtriCure logoAtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ATRC
  • CUSIP: 04963C20
  • Web: www.atricure.com
Capitalization:
  • Market Cap: $783.85 million
  • Outstanding Shares: 34,334,000
Average Prices:
  • 50 Day Moving Avg: $21.97
  • 200 Day Moving Avg: $22.04
  • 52 Week Range: $14.78 - $25.18
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -32.15
  • P/E Growth: -1.21
Sales & Book Value:
  • Annual Revenue: $166 million
  • Price / Sales: 4.72
  • Book Value: $4.70 per share
  • Price / Book: 4.86
Profitability:
  • EBITDA: ($19,620,000.00)
  • Net Margins: -19.56%
  • Return on Equity: -19.56%
  • Return on Assets: -11.91%
Debt:
  • Debt-to-Equity Ratio: 0.21%
  • Current Ratio: 2.56%
  • Quick Ratio: 1.93%
Misc:
  • Average Volume: 198,020 shs.
  • Beta: 0.84
  • Short Ratio: 13.26
 

Frequently Asked Questions for AtriCure (NASDAQ:ATRC)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings data on Thursday, July, 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.05. The firm had revenue of $45.23 million for the quarter, compared to the consensus estimate of $44.15 million. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. The business's revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.26) EPS. View AtriCure's Earnings History.

When will AtriCure make its next earnings announcement?

AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for AtriCure.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $(1.04)-(0.94) for the period, compared to the Thomson Reuters consensus estimate of ($0.96). The company issued revenue guidance of $177-178 million, compared to the consensus revenue estimate of $175.85 million.

Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?

7 brokerages have issued twelve-month target prices for AtriCure's shares. Their forecasts range from $24.00 to $28.00. On average, they anticipate AtriCure's stock price to reach $25.83 in the next year. View Analyst Ratings for AtriCure.

What are analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:

  • 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (10/2/2017)
  • 2. Needham & Company LLC analysts commented, "ATRC’s 2Q17 revenue, EBITDA, and EPS beat consensus and management raised its 2017 revenue guidance. Worldwide Open-Heart Ablation growth improved to 11% from 10% in 1Q17 and US Open-Heart Ablation growth improved to 14% from 12% in 1Q17. We think that the accelerating Open-Heart growth should help to reduce concerns that this business is in a permanent slowdown and we think this shows that the new guidelines for ablation in concomitant open-heart procedures are driving stronger growth in this business. ATRC shares remain at a large discount to peers (2017E EV/sales of 4.4x vs. small/mid-cap growth peers at a median of 7.1x) and we reiterate our Buy rating." (7/28/2017)

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:

  • Richard M. Johnston, Independent Chairman of the Board
  • Michael H. Carrel, President, Chief Executive Officer, Director
  • M. Andrew Wade CPA, Chief Financial Officer, Senior Vice President
  • Douglas J. Seith, Chief Operating Officer
  • Justin J. Noznesky, Senior Vice President, Marketing and Business Development
  • Andrew L. Lux Ph.D., Senior Vice President -Operations and Quality
  • Salvatore Privitera, Chief Technology Officer
  • Mark A. Collar, Independent Director
  • Scott William Drake, Independent Director
  • Regina E. Groves, Independent Director

How do I buy AtriCure stock?

Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of AtriCure stock can currently be purchased for approximately $22.83.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AtriCure (NASDAQ:ATRC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $25.83 (13.16% upside)
Consensus Price Target History for AtriCure (NASDAQ:ATRC)
Price Target History for AtriCure (NASDAQ:ATRC)
Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Canaccord GenuityReiterated RatingBuy$28.00N/AView Rating Details
7/30/2017Stifel NicolausReiterated RatingBuy$25.00MediumView Rating Details
7/28/2017Needham & Company LLCReiterated RatingBuy -> Buy$25.00 -> $26.00HighView Rating Details
6/16/2017Leerink SwannReiterated RatingOutperform$26.00LowView Rating Details
5/30/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$26.00LowView Rating Details
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00LowView Rating Details
3/6/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for AtriCure (NASDAQ:ATRC)
Earnings by Quarter for AtriCure (NASDAQ:ATRC)
Earnings History by Quarter for AtriCure (NASDAQ ATRC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017($0.21)N/AView Earnings Details
7/27/2017Q2 2017($0.26)($0.21)$44.15 million$45.23 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.33)($0.32)$40.25 million$41.30 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.32)($0.27)$41.17 million$41.20 millionViewListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AtriCure (NASDAQ:ATRC)
2017 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AtriCure (NASDAQ:ATRC)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 82.11%
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Elizabeth D KrellDirectorSell10,000$22.40$224,000.00View SEC Filing  
5/17/2017Elizabeth D KrellDirectorSell10,000$21.44$214,400.00View SEC Filing  
3/17/2017Andrew L LuxSVPSell20,000$18.85$377,000.00View SEC Filing  
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.00View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.00View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.00View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.00View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.00View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.00View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.00View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.00View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AtriCure (NASDAQ:ATRC)
Latest Headlines for AtriCure (NASDAQ:ATRC)
Source:
Loading headlines, please wait.

Social

Chart

AtriCure (ATRC) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.